Avid Bioservices Inc (CDMO)

[Protector]

vinmantoo, of course there is evidence. 60% SOC improvement in PII NSCLC. While the others, the PS receptor approach, have no such results at all.


So the PS receptor targeting is worse then 'repeatedly' because it is ALWAYS and Bavi NEVER failed in combination with I-O. Furthermore MSK, NCCN, AstraZeneca (and possible Merck - we need to know if Bavi is just combined with KeyTruda or if MRK themselves are involved) are working with Bavi in IO and not with TIM's (1,3,4) TAM's (Axl, Her, etc) or any of the others at all or in that extend for combo's.